Linking amyloid-β and tau deposition in Alzheimer disease

JAMA Neurology

Volumn 74, Issue 7, 2017, Pages 766-768

  Vemuri, Prashanthi ^a   Schöll, Michael ^b,c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN; AMYLOID;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DEMENTIA; DISEASE CLASSIFICATION; DISEASE COURSE; EDITORIAL; ENTORHINAL CORTEX; HIPPOCAMPUS; HUMAN; NEUROIMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; AMYLOID PLAQUE; BRAIN CORTEX;

ALZHEIMER DISEASE; AMYLOID; CEREBRAL CORTEX; HUMANS; PLAQUE, AMYLOID; TAU PROTEINS;

EID: 85024387305     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2017.0323     Document Type: Editorial

References (15)

1. Dubois B, Hampel H, Feldman HH, et al; Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on "The Preclinical State of AD"; July 23, 2015;Washington DC, USA. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3): 292-323.
2. Jack CR Jr, AlbertMS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3): 257-262.
3. Villemagne VL, Burnham S, Bourgeat P, et al; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357-367.
4. Ingelsson M, Fukumoto H, Newell KL, et al. Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62(6):925-931.
5. Ossenkoppele R, Schonhaut DR, Scholl M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016;139(pt 5):1551-1567.
6. Xia C, Makaretz SJ, Caso C, et al. Association of in vivo 18F-AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease. JAMA Neurol. 2017;74 (4):427-436.
7. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351-357.
8. Sepulcre J, Grothe MJ, Sabuncu M, et al. Hierarchical organization of tau and amyloid deposits in the cerebral cortex [published online May 30, 2017]. JAMA Neurol. doi:10.1001/jamaneurol.2017.0263
9. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79 (1):110-119.
10. Lockhart SN, Scholl M, Baker SL, et al. Amyloid and tau PET demonstrate region-specific associations in normal older people. Neuroimage. 2017;150:191-199.
11. Vemuri P, Lowe VJ, Knopman DS, et al. Tau-PET uptake: regional variation in average SUVR and impact of amyloid deposition. Alzheimers Dement (Amst). 2016;6:21-30.
12. Cho H, Choi JY, Hwang MS, et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology. 2016;87(4):375-383.
13. Brier MR, Gordon B, Friedrichsen K, et al. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Sci Transl Med. 2016;8(338): 338ra66.
14. Scholl M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971-982.
15. Schwarz AJ, Yu P, Miller BB, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139(pt 5):1539-1550.